Targeting the PI3K-mTOR Network in Cancer

Sept. 14-17, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pa.

Conference Co-Chairpersons
Lewis C. Cantley, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, N.Y.
José Baselga, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Joan S. Brugge, Harvard Medical School, Boston, Mass.
Brendan D. Manning, Harvard School of Public Health, Boston, Mass.
Malte Peters, Novartis Pharma AG, Basel, Switzerland

This AACR Special Conference will highlight recent progress in understanding the molecular wiring of the PI3K-mTOR signaling network and its activation in cancer, the major downstream functions contributing to cancer pathology, and therapeutic strategies for targeting the network and overcoming resistance. An expert line-up of researchers and clinicians working at the leading edge of discovery and translation, in both academic and industry settings, has been assembled to cover these topics in an interdisciplinary manner. Talks will range from structural, pharmacological, and mechanistic insights to genetic mouse models and results from clinical trials. The program is designed to foster interactions between basic and clinical investigators and to emphasize critical discussions around the most pressing topics. Opportunities for early career researchers and trainees to present through oral and poster presentations are an important part of the program.

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available